FORM	4
------	---

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(

Π

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(b) of the

continue. Se 1(b).	ee Instruction	17(a) of the Publ	ic Utility Holding Company Act of 1935 or Section Investment Company Act of 1940	hours per response	0.5		
1. Name and Address of Reporting Person <sup>*</sup> Schenkein David P			2. Issuer Name <b>and</b> Ticker or Trading Symbol AGIOS PHARMACEUTICALS INC [AGIO]	5. Relationship of Reporting Person(s) to Issuer			
SIDNEY STRI	.ast) (First) (Middle)		3. Date of Earliest Transaction (Month/Day/Year) 03/05/2014	<ul> <li>(Check all applicable)</li> <li>X Director</li> <li>X Officer (give title below)</li> <li>Chief Executive</li> </ul>		10% Owner Other (specify below) e Officer	
(Street) CAMBRIDGE (City)	MA (State)	02139 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual o (Check Applica X Form filed b Form filed b Reporting P	porting Person		

	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				6. Ownership Form: Direct (D)	Beneficial Ownership			
			Code	V	(A) or Amount (D)		Price	Following or Indirect Reported (I) Transaction(s) (Instr. 4) (Instr. 3 and 4)		(Instr. 4)			

## OMB APPROVAL

OMB Number:	3235-0287							
Expires:	December 31, 2014							
Estimated average burden								
hours per response	0.5							

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned         (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Instr. 8)		of Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		Amount of Underlying		Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$ 31.64	03/05/2014		A		160,000		(1)	03/04/2024	Common Stock	160,000	\$0	841,774	D	

**Explanation of Responses:** 

1. This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the underlying shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.

/s/ Glenn Goddard, as <u>Attorney-in-Fact for David</u> <u>Schenkein</u> \*\* Signature of Reporting Person
Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.